SCHEMBL3752142

SCHEMBL3752142

CC(C)C[C@@H](NC(=O)OC(C)(C)C)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 2/20 0.48
▸ CTSK P43235 2/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSS P25774 1/20 0.48
▸ CAPN1 P07384 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.42
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MAP1LC3B Q9GZQ8 1/20 0.40
▸ MAP1LC3A Q9H492 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MEN1 O00255 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3752138 1.00 CTSL (0.48) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL12657499 1.00 CTSL (0.48) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL18206273 0.92 CTSL (0.44) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL18206276 0.92 CTSL (0.44) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL18206277 0.92 CTSL (0.44) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL23771861 0.89 CTSL (0.40) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL18916653 0.88 CTSK (0.42) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL18762624 0.88 CTSS (0.37) CTSLCTSKCTSBCTSSCAPN1
SCHEMBL10347068 0.87 CYP1A2 (0.38) CTSLCTSKCTSBCTSSCA1
SCHEMBL22199794 0.87 CTSK (0.46) CTSLCTSKCTSBCTSSCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347034-A1 PROTEASE INHIBITORS AS ANTIVIRALS ACEA Therapeutics, Inc. (US) 2024-04-10 — — EP disclosed
US-11802110-B2 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase Oxford Drug Design Limited (GB) 2023-10-31 — — US disclosed
US-11802110-B2 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase Oxford Drug Design Limited (GB) 2023-10-31 — — US disclosed
WO-2022256434-A1 PROTEASE INHIBITORS AS ANTIVIRALS ACEA Therapeutics, Inc. (US) 2022-12-08 — — WO disclosed
WO-2022256434-A1 PROTEASE INHIBITORS AS ANTIVIRALS ACEA Therapeutics, Inc. (US) 2022-12-08 — — WO disclosed
US-20200039929-A1 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE INHIBOX LIMITED (GB) 2020-02-06 — — US disclosed
US-8362015-B2 Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-01-29 — — US disclosed
US-20100292230-A1 Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802110-B2 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase AARS1, NSUN3, GARS1 CTSL 1733/4885CTSK 3008/4885CTSB 1495/4885
US-20200039929-A1 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE AARS1, NSUN3, GARS1 CTSL 1733/4885CTSK 3008/4885CTSB 1495/4885
US-20100292230-A1 Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders AADAC, AADAT, DNPEP CTSL 211/4885CTSK 1758/4885CTSB 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback